← Who reports today · Health Care
AMGN earnings date & Q2 2026 results · Amgen
US GAAP · $M · vs Q2 2025 · quarter ended 06/30/2026 · reported 08/04/2026
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. · Wikipedia
More about the company
The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. Market share (US pharma & biotech): ≈5% by TTM revenue.
Key growth driver: Repatha — the fastest-growing revenue line: $953, +37% y/y. · by the Q2 2026 report
When is AMGN’s next earnings date?
Tuesday, November 3, 2026estimated
Amgen (AMGN) has not confirmed the date yet; Nov 3, 2026 is an estimate based on the company's past reporting schedule and may move once the date is announced. Consensus EPS forecast: $5.69 (9 analysts), vs $5.64 in the same quarter last year.
What time does AMGN report? Usually after market close: the last 4 results releases reached the SEC at 4:03 pm, 4:03 pm, 4:03 pm, 4:04 pm ET.
Last report: Aug 4, 2026 (Q2 2026) — broken down in the Sankey chart below. Dates and consensus: Nasdaq / Zacks Investment Research; companies do reschedule. Who else reports this week →
All figures in $M.
Revenue
$10,054
+9.5%
Gross profit
$7,243
+17.4%
72.0% margin, was 67.2%
Operating income
$3,514
+32.3%
35.0% margin
Net income
$2,375
+65.9%
$4.37 diluted EPS
Verdict: revenue rose 9.5% to $10.1B and net income 65.9% to $2.4B — but the profit jump is mostly the fading of acquisition accounting: inventory step-up amortisation from the Horizon deal fell from $339M to $60M, so cost of sales dropped 6.6% while sales grew. Underneath, the launch drugs are outrunning the biosimilar losses.
Diluted EPS $4.37 vs $2.65. Interest expense, net $673M — the Horizon debt still costs a fifth of operating income. Amgen reports a single segment (human therapeutics), so the split below is by product, not by division.
Source and notation
* marks non-cash / ≈ estimated. Source: Amgen 10-Q for the quarter ended June 30, 2026 (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
AMGN earnings history: past report dates
| Aug 4, 2026 Tue | 4:03 pmafter market close | Jun 30, 2026 | $10.1B+10% y/y | $4.37+65% y/y |
| Apr 30, 2026 Thu | 4:03 pmafter market close | Mar 31, 2026 | $8.6B+6% y/y | $3.34+4% y/y |
| Feb 3, 2026 Tue | 4:03 pmafter market close | Dec 31, 2025 | ≈$9.9B+9% y/y | ≈$2.45+109% y/y |
| Nov 4, 2025 Tue | 4:04 pmafter market close | Sep 30, 2025 | $9.6B+12% y/y | $5.93+14% y/y |
| Aug 5, 2025 Tue | 4:03 pmafter market close | Jun 30, 2025 | $9.2B+9% y/y | $2.65+92% y/y |
| May 1, 2025 Thu | 4:04 pmafter market close | Mar 31, 2025 | $8.1B+9% y/y | $3.20 |
| Feb 4, 2025 Tue | 4:05 pmafter market close | Dec 31, 2024 | ≈$9.1B+11% y/y | ≈$1.17−18% y/y |
| Oct 30, 2024 Wed | 4:06 pmafter market close | Sep 30, 2024 | $8.5B+23% y/y | $5.22+62% y/y |
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Amgen: 5-year financials
| 2025 | 36,751 | 9,080 | 7,711 | 8,100 | 5,124 |
| 2024 | 33,424 | 7,258 | 4,090 | 10,394 | 4,832 |
| 2023 | 28,190 | 7,897 | 6,717 | 7,359 | 4,556 |
| 2022 | 26,323 | 9,566 | 6,552 | 8,785 | 4,196 |
| 2021 | 25,979 | 7,639 | 5,893 | 8,381 | 4,013 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP).
How we calculate
Figures are the annual report lines as filed, no adjustments. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing.
Corporate governance
1.5/2mostly good
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
More
- Oct 2016The court granted final approval of the settlement in In re Amgen Inc. Securities Litigation (a suit over 2004–2007 statements on Aranesp/Epogen; the $95M amount was announced in 07/2016). sec.gov ↗
- Feb 2026The 2025 10-K discloses an unresolved class action, Roofers Local No. 149 (2023), over disclosure of a tax dispute with the IRS. sec.gov ↗
- Dec 2025Diluted shares −8% over 2020–2025; SBC of $0.49B = 1.3% of revenue; the dividend rose from $6.56 to $9.66 per share. data.sec.gov ↗
Scoring: 2.0 −0.5 (criterion 9: investor suit over Aranesp/Epogen settled for $95M; settlement approved by the court in Oct 2016, within 10 years) = 1.5
- Share classes
- Single class of common stock (2025 10-K cover).
- Dilution
- Diluted shares −8% over 2020–2025, SBC 1.3% of revenue.
- Disclosure
- Full US GAAP reporting: 10-K and 10-Q filed on EDGAR on time.
- Dividends
- Dividend raised every year ($6.56 → $9.66 over 2020–2025); buybacks were nearly absent in 2023–2025 after the all-cash Horizon acquisition — no buyback commitments, no deduction.
- Lawsuits & regulators
- 2007 investor suit (Aranesp/Epogen) settled for $95M, court approval in Oct 2016 — full deduction; the Roofers suit (2023, IRS tax dispute) and derivative suits are unresolved — no deduction.
- Related parties
- The 2026 proxy lists only a senior executive's son-in-law on staff (~$0.37M) — immaterial.
How the score works · checked as of Sep 2026
Amgen (AMGN) earnings: FAQ
When is AMGN's next earnings date?
Amgen (AMGN) has not confirmed the date yet; Nov 3, 2026 is an estimate based on its past reporting schedule.
What time does AMGN report earnings?
Amgen usually reports after market close: its latest results release was filed with the SEC at 4:03 pm ET on Aug 4, 2026.
When did AMGN last report earnings?
Amgen reported Q2 2026 results on Aug 4, 2026.
What is the EPS estimate for AMGN's next earnings?
The consensus EPS forecast is $5.69 (9 analysts), vs $5.64 in the same quarter last year.
Where can I find Amgen's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to AMGN's filings; this page breaks the latest report down in a Sankey chart.
What was AMGN's net income in Q2 2026?
Amgen reported net income of $2,375M for Q2 2026 (+65.9% year over year), under US GAAP.
Does Amgen pay dividends?
Yes. In 2025, Amgen paid $5,124M in dividends on its common stock, per its 10-K. Earlier years are in the five-year table above.
New to earnings reports? Start with how to read an earnings report.
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report. Figures checked against the filing on 09/01/2026. How we make the breakdowns · Report an error
More reports: BMY · Q2 2026 · CI · Q2 2026 · CVS · Q2 2026 · DHR · Q2 2026 · ELV · Q2 2026 · GILD · Q2 2026 · HCA · Q2 2026 · ISRG · Q2 2026 · JNJ · Q2 2026 · LLY · Q2 2026 · all reports